Physician profile
Laura Lakin
NPI 1235539503
$1,391.76
in general payments reported to CMS, 2019-2025
13 companies · $255 in 2025
The $255 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $58.38 · 2021: $216 · 2022: $297 · 2023: $117 · 2024: $300 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $668 · Education: $4.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $667.97 |
| Education | $4.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $348.75 | 2022-2025 | Infuse, Miebo, Vyzulta |
| Coopervision INC. | $329.10 | 2019-2024 | Misight Contact Lens, Myday Contact Lens |
| Allergan, INC. | $134.51 | 2021-2022 | |
| Abbvie INC. | $116.88 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $97.94 | 2019-2021 | |
| Sight Sciences, INC. | $59.21 | 2019-2020 | |
| Dompe US, INC. | $53.25 | 2022-2025 | Oxervate |
| Alcon Vision LLC | $51.76 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $48.00 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $46.67 | 2022 | |
| Glaukos Corporation | $38.40 | 2021 | |
| Novartis Pharmaceuticals Corporation | $35.43 | 2023 | |
| Abb Con-Cise Optical Group LLC | $31.86 | 2025 | Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Lakin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.